(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) have treated the first patient, outside of the U.S., in their phase 2/3 trial evaluating the rheumatoid arthritis drug Kevzara in patients hospitalized with severe COVID-19.
This trial, initiated in Italy, Spain, Germany, France and Japan, is expected to enroll approximately 300 patients.
Earlier this month, the Companies initiated a phase 2/3 trial evaluating Kevzara in adult patients hospitalized with severe or critical COVID-19 in the U.S. This study is expected to enroll 400 patients.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
